Click Therapeutics

News

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.

News

Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.

Digital

Click Therapeutics CEO David Benshoof Klein shares thoughts on what's been holding DTx back and why this could be the moment for a breakout.

News

Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.

News

Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.

News

A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.